Exhibit 99.1 Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., February 24, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on ...

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial ...

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer ...

Corporate Overview February 2026 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. 1 Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potentia ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 13 Best American Penny Stocks to Invest In. On February 6, H.C. Wainwright reiterated its Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $9 on the stock. This update followed the company’s February 5 announcement of data showing a best-in-class profile for its commercial therapy Amtagvi (lifileucel). Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shared that the treatment delivered unprecedented response rates in a re ...

Core Viewpoint - Iovance Biotherapeutics is positioned for significant growth due to its recent product approval and ongoing studies across multiple cancer indications, making it an attractive investment opportunity in the biotech sector [4][10]. Company Overview - Iovance Biotherapeutics has achieved approval for its first product, lifileucel, commercialized as Amtagvi, which targets melanoma that cannot be completely removed by surgery or has metastasized [4]. - The company has a market capitalization of $1.1 billion, with current stock trading at $2.87 [5][6]. Financial Performance - Iovance is not yet profitable, which is typical for biotech firms at this stage, but it reported a 13% increase in revenue to $68 million in the latest quarter [7]. - The stock has shown a price range of $1.64 to $5.88 over the past 52 weeks, indicating volatility and potential for growth [6]. Product and Treatment Efficacy - Amtagvi is a tumor-infiltrating lymphocyte (TIL) treatment that reinvigorates a patient's own TIL to combat cancer cells [6]. - A recent study indicated a 52% objective response rate for Amtagvi in real-world conditions, surpassing the 31% response rate from the clinical trial that led to its accelerated approval [8]. Pipeline and Future Prospects - Iovance is exploring lifileucel for various cancer types and in combination with other treatments, with many trials currently in phase 2, suggesting potential for additional indications soon [9]. - The stock is accessible for investors at under $3, with the potential for significant appreciation if the pipeline proves successful [10].

Group 1 - Iovance Biotherapeutics Inc. is recognized as a promising immunotherapy stock by hedge funds, with Goldman Sachs raising its price target to $2 from $1.50 while maintaining a Sell rating [1] - The company announced data showcasing a best-in-class profile for its commercial product Amtagvi, demonstrating unprecedented response rates in a real-world clinical study for advanced melanoma patients [2] - Amtagvi is noted as the first one-time T cell therapy for solid tumor cancer and the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy [3] Group 2 - In a study involving 41 evaluable patients with previously treated advanced melanoma, the physician-assessed confirmed objective response rate for Amtagvi was 44%, with a disease control rate of 73% [4] - Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocyte (TIL) therapies, with Amtagvi being its lead product candidate [5]

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Viewpoint - Iovance Biotherapeutics, Inc. will host a conference call and live audio webcast on February 24, 2026, to report its fourth quarter and full year 2025 financial results and corporate updates [1]. Company Overview - Iovance Biotherapeutics, Inc. focuses on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [3]. - The company is pioneering a transformational approach to cancer treatment by utilizing the human immune system to recognize and destroy diverse cancer cells [3]. - Iovance's TIL platform has shown promising clinical data across multiple solid tumors, and its product Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication [3]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve the lives of cancer patients [3].

Group 1 - Iovance Biotherapeutics Inc. expects to achieve full-year 2025 revenue guidance of $250 to $300 million in the first full calendar year of Amtagvi sales [1][2] - Amtagvi, the treatment regimen for advanced melanoma, is projected to have peak sales potential of up to $1 billion [1] - The company has $307 million in cash and cash equivalents, which will fund operations through the second quarter of 2027 [2] Group 2 - Lifileucel, an in-development treatment for lung cancer, has a commercial opportunity that could be up to 7 times larger than the current melanoma treatment market [2] - Enrollment and data updates for Lifileucel are expected to be completed this year, with a launch anticipated in the second half of 2027 [2] - Iovance Biotherapeutics specializes in developing and commercializing cell therapies as novel cancer immunotherapy products [2]